Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments

EP: 1.The Pathophysiology of Chronic Spontaneous Urticaria

EP: 2.Hallmark Symptoms of Chronic Spontaneous Urticaria

EP: 3.The Epidemiology Associated With Chronic Spontaneous Urticaria 

EP: 4.Differential Diagnosis When Considering Chronic Spontaneous Urticaria 

EP: 5.Healthcare Specialties Involved in Managing Patients With Chronic Spontaneous Urticaria 

EP: 6.Therapies Typically Used in the Firstline For Patients With Chronic Spontaneous Urticaria 

EP: 7.Approaches to Switching Between Antihistamines and Other Medications When Treating Patients with Chronic Spontaneous Urticaria 

EP: 8.The Use of Systemic Corticosteroids In Chronic Spontaneous Urticaria Treatment

Now Viewing

EP: 9.Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments

EP: 10.Key Updates Needed in Chronic Spontaneous Urticaria Guidelines

EP: 11.The Evaluation of Dupilumab In Chronic Spontaneous Urticaria Treatment

EP: 12.Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment

EP: 13.Patient Education, Provider Education, and Overall Final Thoughts

Video content above is prompted by the following:

• A significant percentage (30%-50%) of patients are still symptomatic with chronic spontaneous urticaria while on certain recommended doses. What do you believe accounts for this high number of patients who are not responding adequately?
  • Patients have to come in for first 3 doses because this a biologic. Is this preferred? Is there a burden on these patients?
  • Said prescription targets the IgE pathway, but a significant percentage of patients have IgG antibodies as part of their disease pathophysiology. What do you do in your patients who do not respond to this prescription?
  • Why is it imperative to develop new treatments that target the IgG pathway?